Arthneeti

Aakaar Medical Technologies Q2 FY27 Share Price & Earnings Call Analysis

₹71.00+1.50% today
Market cap
₹101 Cr
P/E
15.15
ROE
17.07%
PEG
0.31
Price to sales
1.52
Debt to equity
0.34
52W high / low
₹87.0 / ₹48.0
Sales growth (5Y)
40.02%
EBITDA margin
15.41%
Net profit margin
9.92%
Promoter holding
67.05%
Sales (last year)
₹67 Cr

Incorporated in June 2013, Aakaar Medical Technologies Limited is an aesthetic medical company that offers a diverse selection of specialized cosmetic products and devices.[1]

Guidance scorecard · Q2 FY27 call

What Aakaar Medical's management guided
and where it ranks in Personal Products

Revenue20–40%MarginsFlatCapexNone plannedFundraisingWhat management saidOrder bookWhat management said

RevenueQ4 FY26 call

20–40%
  • Targeting a CAGR of 30% going forward to maintain strong growth.
  • New brands like Letybo, Xomage, and VM Portfolio expected to significantly boost top line.
  • Focus on growing top 10 brands, currently contributing 65-67% of revenue.
  • Expansion plans include increasing presence in hair transplant and consumables markets.
  • Xelix clinic platform to drive growth by integrating marketing and expanding doctor participation.
  • Hair care category with proprietary products like DRS1512 has potential to reach several hundred crores in revenue.
  • Expected growth driven by stabilized portfolio, launch of new products, and USFDA-approved filler.

2 more points from Aakaar Medical's call on revenue

Create a free account to keep reading this call

Full Q4 FY26 analysis

MarginsQ4 FY26 call

Flat

See what Aakaar Medical said on margins — free account, 30 seconds.

Full Q4 FY26 analysis

CapexQ4 FY26 call

None planned
  • Currently, there is no major CAPEX planned for clinic expansion as the Xelix clinic model is doctor-operated with no direct CAPEX from Aakaar; clinics are tied up under the Xelix platform without ownership by the company.
  • Future plans may involve taking franchise fees from new doctors in the Xelix platform, indicating potential strategic investment in scaling this platform.
  • Investment is underway in manufacturing and developing an exclusive hair transplant device, aiming for patenting and improving transplant success rates, which is an early-stage strategic capital commitment.

2 more points from Aakaar Medical's call on capex

Create a free account to keep reading this call

Full Q4 FY26 analysis

FundraisingQ4 FY26 call

See what Aakaar Medical said on fundraising — free account, 30 seconds.

Full Q4 FY26 analysis

Order bookQ4 FY26 call

Ask what Aakaar Medical said on the order book →

Full Q4 FY26 analysis
Full Personal Products ranking

Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.

Potential multibaggers · Q2 FY27

Potential multibaggers in Personal Products
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Honasa Consumer LtdGood growth
    3
See all potential multibaggersWhere does Aakaar Medical rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Personal Products companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹2,041 Cr61.0
240%+Flat₹400 Cr35.6
3Honasa Consumer Ltd20–40%Up 0–2%₹14,745 Cr58.4
410–20%Flat₹87,493 Cr42.1
510–20%Flat₹68,298 Cr34.4
610–20%Flat₹16,419 Cr21.7

Sign up free to see every company in the sector ranking and track Aakaar Medical.

Pro shows every company guiding 40%+ revenue growth →Full Personal Products ranking

Financials of Aakaar Medical

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Shareholder Pattern

Aakaar Medical

Shareholding breakup across reporting periods.

Jun 2025Sep 2025Mar 2026Sep 2026
Promoters +67.01%67.01%67.05%67.05%
FIIs +1.87%0.50%0.00%0.00%
DIIs +12.33%10.73%11.17%10.13%
Public +18.79%21.77%21.78%22.82%
No. of Shareholders920603550558

Financials of Aakaar Medical

Quarterly Results

Quarter-by-quarter operating performance

No quarterly results data available for this company yet.

Financials of Aakaar Medical

Profit & Loss

Annual income statement trend

Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales +2312193346626785
Expenses +2012172941525770
Operating Profit31245101016
OPM %13%7%12%11%11%16%15%19%
Other Income +00000011
Interest00001222
Depreciation00000000
Profit before tax212348915
Tax %27%29%26%31%26%26%28%
Net Profit +212236711
EPS in Rs2.010.591.782.363.155.794.697.74
Dividend Payout %0%0%35%24%0%0%0%

Financials of Aakaar Medical

Balance Sheet

Capital structure and asset base

Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital0.100.100.700.700.70101414
Reserves777912134044
Borrowings +644615231919
Other Liabilities +436868612
Total Liabilities1614182334547988
Fixed Assets +00000001
CWIP00000000
Investments00000000
Other Assets +1614182334547987
Total Assets1614182334547988

Financials of Aakaar Medical

Cash Flows

Operating, investing and financing cash movement

Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +-040-3-8-5-8
Cash from Investing Activity +00-0-0-0-00
Cash from Financing Activity +0-2-1181119
Net Cash Flow03-1-20510
Free Cash Flow-040-3-8-5-9
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit10%503%47%-54%-136%-35%-59%

Financials of Aakaar Medical

Ratios

Working capital efficiency and return ratios

Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days118136104114129166203
Inventory Days234366282274247202256
Days Payable28996562324924
Cash Conversion Cycle324403321326344320434
Working Capital Days1892381051029497199
ROCE %8%21%26%23%27%18%

Guidance history

How Aakaar Medical's guidance has moved, call by call

CallRevenueMarginsCapexFundraisingOrder book
Q4 FY26 call →20–40%FlatNone planned——
Q2 FY26 call →20–40%FlatPlanned——

What management guided on each call, newest first. Not investment advice, and not a forecast of returns.

Continue your research

What Aakaar Medical's management said in earlier quarters

Others in Personal Products this season

  • Recode Studios Ltd (Q4 FY26)

    The company plans to sustain marketing spends at about 20% of revenue to support growth and brand visibility, implying continued focus on operating profits…

  • Godrej Consumer Products Ltd (Q2 FY27)

    Consolidated net sales for Q2 FY2027: ₹4,396 crore, up 19% year-on-year; constant currency growth 15% (Page 8) . Key investor presentation takeaways from Godrej

  • Colgate-Palmolive (India) Ltd (Q2 FY27)

    1,692 crore, up 12.2% year-on-year from Rs. Key results statement takeaways from Colgate-Palmolive (India) Ltd's Q2 FY27 results statement — and how it ranks ag

  • Anondita Medicare Ltd (Q3 FY26)

    Revenue from operations (Standalone) for H1 FY26: ₹4,765.06 lakh; H1 FY25: ₹2,497.06 lakh; YoY growth: 91% (Page 26) . Key investor presentation takeaways from

Compare:vs Godrej Consumer Products Ltdvs Dabur India Ltdvs Cupid Ltd